← Eichor
Study identifier: NCT06901245 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Tirzepatide in PWS, HO and GNSO

Condition: Prader-Willi Syndrome · Hypothalamic Obesity · Obesity/Therapy  ·  Sponsor: Grace Kim

PhasePhase 4
Planned participants36
Who can joinAll sexes, 18 Years to 26 Years
Healthy volunteersNo

About this study

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (3)

Children's MinnesotaSaint Paul, Minnesota, United StatesRecruiting
Vanderbilt University Medical CenterNashville, Tennessee, United StatesRecruiting
Seattle Children's HospitalSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06901245